Conventional Disease-Modifying Antirheumatic Drugs in Early Arthritis

This publication has 63 references indexed in Scilit:

• Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities
  Annals of the Rheumatic Diseases, 2005
• Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review
  Rheumatology, 2002
• Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis
  Arthritis & Rheumatism, 2000
• Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
  Annals of the Rheumatic Diseases, 1999
• Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial
  Rheumatology, 1997
• Use of short‐term efficacy/toxicity tradeoffs to select second‐line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
  Arthritis & Rheumatism, 1992
• The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis results of two metaanalyses
  Arthritis & Rheumatism, 1990
• Treatment of rheumatoid arthritis.
  BMJ, 1978
• Effect of Gold on Progression of Erosions in Rheumatoid Arthritis: Better Results with Early Treatment
  Scandinavian Journal of Rheumatology, 1977
• The Course of Rheumatoid Arthritis in Patients Receiving Simple Medical and Orthopedic Measures
  New England Journal of Medicine, 1948